Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00547
|
|||||
Drug Name |
Fluorescein
|
|||||
Synonyms |
fluorescein; Solvent Yellow 94; Resorcinolphthalein; Yellow fluorescein; 3',6'-Dihydroxy-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one; D and C Yellow No. 7; Fluoresceine; 3,6-Fluorandiol; D&C Yellow No. 7; Japan Yellow 201; C.I. Solvent Yellow 94; 3',6'-Dihydroxyfluoran; Fluorescein acid; Fluoreszein; D & C Yellow no. 7; Soap Yellow F; Hidacid fluorescein; Fluorescein sodium; D+C Yellow No. 7; 9-(o-Carboxyphenyl)-6-hydroxy-3-isoxanthenone; Fluorescein Red; 11712 Yellow
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Ocular disease [ICD11: 9E1Z] | Approved | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C20H12O5
|
|||||
Canonical SMILES |
C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O
|
|||||
InChI |
InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
|
|||||
InChIKey |
GNBHRKFJIUUOQI-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 518-45-6
|
|||||
Pharmaceutical Properties | Molecular Weight | 332.3 | Topological Polar Surface Area | 76 | ||
Heavy Atom Count | 25 | Rotatable Bond Count | 0 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
3.4
|
|||||
PubChem CID | ||||||
ChEBI ID |
CHEBI:31624
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [2] | |
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
MRP5 | Transporter Info | Multidrug resistance-associated protein 5 | Substrate | [4] | ||
OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [5] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [6] | ||
OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [7] | ||
References | ||||||
1 | Fluorescein was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9. | |||||
3 | Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76. | |||||
4 | Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004. | |||||
5 | Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86. | |||||
6 | Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. | |||||
7 | Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.